Promega Secures Patent Victory Against Aobious in Luciferase Technology Dispute
核心洞察
Promega Corporation (搜索) successfully resolved a patent infringement lawsuit against Aobious Inc. (搜索), with a U.S. District Court confirming Aobious violated four patents related to furimazine (搜索) substrate compounds.
The settlement includes a permanent injunction preventing Aobious from further infringement and requires monetary payments to Promega as part of the agreed terms.
The dispute centered on furimazine (搜索), a substrate for Promega's NanoLuc® luciferase (搜索) technology that produces exceptionally bright luminescent signals for protein research in live cells.
Promega Corporation (搜索) has successfully resolved a patent infringement lawsuit against Aobious Inc. (搜索), securing a favorable settlement that protects its proprietary bioluminescence technology. On July 15, 2025, the U.S. District Court for the District of Delaware entered a final Consent Judgment confirming that Aobious infringed four Promega patents covering luciferase substrate compounds, specifically furimazine (搜索) and its associated variants.
Settlement Terms and Legal Victory
The settlement agreement includes a permanent injunction against Aobious, preventing the company from further patent infringement activities. Additionally, Aobious is required to make monetary payments to Promega as agreed upon in the settlement terms, though specific financial details were not disclosed.
"Defending our intellectual property supports our mission of providing high-quality, innovative tools to scientists around the world," says Kevin Kopish, Promega Associate Director of Cell & Protein Analysis. "Acquiring bioluminescence reagents through authorized channels not only ensures that they are optimal quality, but it also supports our continued investment in developing new technologies to advance scientific research."
Furimazine Technology and Applications
The dispute centered on furimazine (搜索), a substrate for NanoLuc® luciferase (搜索), a novel enzyme that Promega introduced in 2012. When NanoLuc® luciferase interacts with its substrate, it produces an exceptionally bright luminescent signal that has become valuable for various research applications.
Promega's assay platforms, including NanoBiT® and Lumit® technologies, enable researchers to utilize this luminescent signal to study proteins in live cells. The company has strategically licensed several of these technologies to authorized partners, allowing them to develop solutions for specific customer needs, including applications in CRISPR-edited cell lines.
Research and Development Investment
Promega continues to advance its bioluminescence-based research tools centered on NanoLuc® luciferase (搜索) and furimazine (搜索) technology. In 2024, the company demonstrated its commitment to innovation by investing 13.8% of its revenue into research and development, a figure that surpasses industry averages.
The company's portfolio encompasses over 4,000 products supporting various life science applications, including cell biology, DNA, RNA and protein analysis, drug development, human identification, and molecular diagnostics. These tools serve scientists and technicians across academic and government research, forensics, pharmaceuticals, clinical diagnostics, and veterinary, agricultural and environmental testing sectors.
Market Position and Distribution
Promega Corporation (搜索), headquartered in Madison, Wisconsin, operates with branches in 16 countries and maintains relationships with over 50 global distributors. The company has established itself as a leader in providing innovative solutions and technical support to the life sciences industry over its 45-year history.
The settlement reinforces Promega's commitment to protecting its intellectual property while ensuring that high-quality bioluminescence reagents reach the scientific community through authorized distribution channels.